Education
About Us
Working with TipRanks
Follow Us
Axsome Therapeutics Inc (GB:0HKF)
LSE:0HKF
0HKF Analyst Ratings
Strong Buy
17 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
0HKF Stock 12 Month Forecast
Average Price Target
$173.50
▲(45.57% Upside)
| Highest Price Target$212.00 | Average Price Target$173.50 | Lowest Price Target$133.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Piper Sandler
Reiterated
03/11/25
Truist Financial
Reiterated
03/06/25
TD Cowen
Reiterated
03/06/25
H.C. Wainwright
Reiterated
03/06/25
Mizuho Securities
Reiterated
03/06/25
Robert W. Baird
Reiterated
03/03/25
William Blair
Reiterated
03/03/25
Wells Fargo
Reiterated
03/03/25
Needham
Reiterated
03/03/25
Morgan Stanley
Reiterated
03/03/25
Leerink Partners
―
Buy
―
Reiterated
02/24/25
Positive Outlook for Axsome Therapeutics Driven by Symbravo's Promising Study Results and Market Potential
Guggenheim
$135→$195
Buy
63.60%
Upside
Reiterated
02/19/25
Axsome Therapeutics price target raised to $195 from $135 at GuggenheimAxsome Therapeutics price target raised to $195 from $135 at Guggenheim
Cantor Fitzgerald
$124→$153
Buy
28.37%
Upside
Reiterated
02/18/25
Cantor Fitzgerald Reaffirms Their Buy Rating on Axsome Therapeutics (AXSM)
RBC Capital
$143→$192
Buy
61.09%
Upside
Reiterated
02/18/25
RBC Capital Reaffirms Their Buy Rating on Axsome Therapeutics (AXSM)
Bank of America Securities
$167
Buy
40.11%
Upside
Reiterated
02/18/25
Promising Growth and Market Expansion Drive Buy Rating for Axsome Therapeutics
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Piper Sandler
Reiterated
03/11/25
Truist Financial
Reiterated
03/06/25
TD Cowen
Reiterated
03/06/25
H.C. Wainwright
Reiterated
03/06/25
Mizuho Securities
Reiterated
03/06/25
Robert W. Baird
Reiterated
03/03/25
William Blair
Reiterated
03/03/25
Wells Fargo
Reiterated
03/03/25
Needham
Reiterated
03/03/25
Morgan Stanley
Reiterated
03/03/25
Leerink Partners
―
Buy
―
Reiterated
02/24/25
Positive Outlook for Axsome Therapeutics Driven by Symbravo's Promising Study Results and Market Potential
Guggenheim
$135→$195
Buy
63.60%
Upside
Reiterated
02/19/25
Axsome Therapeutics price target raised to $195 from $135 at GuggenheimAxsome Therapeutics price target raised to $195 from $135 at Guggenheim
Cantor Fitzgerald
$124→$153
Buy
28.37%
Upside
Reiterated
02/18/25
Cantor Fitzgerald Reaffirms Their Buy Rating on Axsome Therapeutics (AXSM)
RBC Capital
$143→$192
Buy
61.09%
Upside
Reiterated
02/18/25
RBC Capital Reaffirms Their Buy Rating on Axsome Therapeutics (AXSM)
Bank of America Securities
$167
Buy
40.11%
Upside
Reiterated
02/18/25
Promising Growth and Market Expansion Drive Buy Rating for Axsome Therapeutics
Best Analysts Covering Axsome Therapeutics
Which Analyst Should I Follow If I Want to Buy GB:0HKF and Sell After:
1 Month
xxx
Success Rate
15/24 ratings generated profit
Average Return
+15.83%
reiterated a xxx
rating 10 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 62.50% of your transactions generating a profit, with an average return of +15.83% per trade.
3 Months
xxx
Success Rate
15/21 ratings generated profit
Average Return
+16.18%
reiterated a xxx
rating 7 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 71.43% of your transactions generating a profit, with an average return of +16.18% per trade.
1 Year
2 Years
xxx
Success Rate
29/30 ratings generated profit
Average Return
+51.13%
reiterated a xxx
rating 7 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 96.67% of your transactions generating a profit, with an average return of +51.13% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
0HKF Analyst Recommendation Trends
Rating
Nov 24
Dec 24
Jan 25
Feb 25
Mar 25
Strong Buy
9
13
16
19
16
Buy
40
42
48
54
49
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
49
55
64
73
65
Each month's total comprises the sum of three months' worth of ratings.
0HKF Financial Forecast
0HKF Stock Forecast FAQ
What is GB:0HKF’s average 12-month price target, according to analysts?
Based on analyst ratings, Axsome Therapeutics Inc’s 12-month average price target is $173.50.
What is GB:0HKF’s upside potential, based on the analysts’ average price target?
Axsome Therapeutics Inc has 45.57% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Axsome Therapeutics Inc a Buy, Sell or Hold?
Axsome Therapeutics Inc has a consensus rating of Strong Buy, which is based on 17 buy ratings, 0 hold ratings and 0 sell ratings.
What is Axsome Therapeutics Inc’s share price target?
The average share price target for Axsome Therapeutics Inc is $173.50. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is $212.00 ,and the lowest forecast is $133.00. The average share price target represents 45.57% Increase from the current price of $119.19.
The highest analyst share price target is $212.00 ,and the lowest forecast is $133.00. The average share price target represents 45.57% Increase from the current price of $119.19.
What do analysts say about Axsome Therapeutics Inc?
Axsome Therapeutics Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 17 Wall Streets Analysts.
How can I buy shares of Axsome Therapeutics Inc?
To buy shares of GB:0HKF, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.